Literature DB >> 22855598

Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.

George Vasmatzis1, Sarah H Johnson, Ryan A Knudson, Rhett P Ketterling, Esteban Braggio, Rafael Fonseca, David S Viswanatha, Mark E Law, N Sertac Kip, Nazan Ozsan, Stefan K Grebe, Lori A Frederick, Bruce W Eckloff, E Aubrey Thompson, Marshall E Kadin, Dragana Milosevic, Julie C Porcher, Yan W Asmann, David I Smith, Irina V Kovtun, Stephen M Ansell, Ahmet Dogan, Andrew L Feldman.   

Abstract

Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies of mature T lymphocytes with 5-year overall survival rates of only ∼ 35%. Improvement in outcomes has been stymied by poor understanding of the genetics and molecular pathogenesis of PTCL, with a resulting paucity of molecular targets for therapy. We developed bioinformatic tools to identify chromosomal rearrangements using genome-wide, next-generation sequencing analysis of mate-pair DNA libraries and applied these tools to 16 PTCL patient tissue samples and 6 PTCL cell lines. Thirteen recurrent abnormalities were identified, of which 5 involved p53-related genes (TP53, TP63, CDKN2A, WWOX, and ANKRD11). Among these abnormalities were novel TP63 rearrangements encoding fusion proteins homologous to ΔNp63, a dominant-negative p63 isoform that inhibits the p53 pathway. TP63 rearrangements were seen in 11 (5.8%) of 190 PTCLs and were associated with inferior overall survival; they also were detected in 2 (1.2%) of 164 diffuse large B-cell lymphomas. As TP53 mutations are rare in PTCL compared with other malignancies, our findings suggest that a constellation of alternate genetic abnormalities may contribute to disruption of p53-associated tumor suppressor function in PTCL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855598      PMCID: PMC5070713          DOI: 10.1182/blood-2012-03-419937

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide arrayCGH approach.

Authors:  Júlia M Sánchez-Schmidt; Rocío Salgado; Octavio Servitje; Fernando Gallardo; Pablo L Ortiz-Romero; Maria B Karpova; Marie C Zipser; M Pilar García-Muret; Teresa Estrach; Socorro M Rodríguez-Pinilla; Fina Climent; Javier Suela; Bibiana I Ferreira; Juan C Cigudosa; Marta Salido; Carlos Barranco; Sergio Serrano; Reinhard Dummer; Francesc Solé; Ramon M Pujol; Blanca Espinet
Journal:  J Invest Dermatol       Date:  2010-09-16       Impact factor: 8.551

2.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

Authors:  Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

Review 3.  Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Authors:  Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Journal:  Drug Resist Updat       Date:  2008-09-17       Impact factor: 18.500

4.  Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma.

Authors:  Maurice Phillip DeYoung; Cory M Johannessen; Chee-Onn Leong; William Faquin; James W Rocco; Leif W Ellisen
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

5.  p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas.

Authors:  M Pinyol; F Cobo; S Bea; P Jares; I Nayach; P L Fernandez; E Montserrat; A Cardesa; E Campo
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

6.  P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome.

Authors:  Alexey Fomenkov; Yi-Ping Huang; Ozlem Topaloglu; Anna Brechman; Motonobo Osada; Tanya Fomenkova; Eugene Yuriditsky; Barry Trink; David Sidransky; Edward Ratovitski
Journal:  J Biol Chem       Date:  2003-04-10       Impact factor: 5.157

7.  Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.

Authors:  Luciano J Costa; Andrew L Feldman; Ivana N Micallef; David J Inwards; Patrick B Johnston; Luis F Porrata; Stephen M Ansell
Journal:  Br J Haematol       Date:  2008-05-15       Impact factor: 6.998

8.  Identification of ANKRD11 as a p53 coactivator.

Authors:  Paul M Neilsen; Kelly M Cheney; Chia-Wei Li; J Don Chen; Jacqueline E Cawrse; Renée B Schulz; Jason A Powell; Raman Kumar; David F Callen
Journal:  J Cell Sci       Date:  2008-10-07       Impact factor: 5.285

Review 9.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

10.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53.

Authors:  M Osada; M Ohba; C Kawahara; C Ishioka; R Kanamaru; I Katoh; Y Ikawa; Y Nimura; A Nakagawara; M Obinata; S Ikawa
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

View more
  87 in total

1.  Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma.

Authors:  Xiaoming Xing; Thomas J Flotte; Mark E Law; Anthony J Blahnik; Wee-Joo Chng; Gaofeng Huang; Ryan A Knudson; Rhett P Ketterling; Julie C Porcher; Stephen M Ansell; Jagmohan Sidhu; Ahmet Dogan; Andrew L Feldman
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-09

2.  Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements.

Authors:  Rebecca L King; Linda N Dao; Ellen D McPhail; Elaine S Jaffe; Jonathan Said; Steven H Swerdlow; Christopher A Sattler; Rhett P Ketterling; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; Sarah E Gibson; Sarah L Ondrejka; Alina Nicolae; William R Macon; Surendra Dasari; Edgardo Parrilla Castellar; Andrew L Feldman
Journal:  Am J Surg Pathol       Date:  2016-01       Impact factor: 6.394

Review 3.  T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.

Authors:  Carla Casulo; Owen O'Connor; Andrei Shustov; Michelle Fanale; Jonathan W Friedberg; John P Leonard; Brad S Kahl; Richard F Little; Lauren Pinter-Brown; Ranjani Advani; Steven Horwitz
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

Review 4.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

5.  Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping.

Authors:  Xueju Wang; Rebecca L Boddicker; Surendra Dasari; Jagmohan S Sidhu; Marshall E Kadin; William R Macon; Stephen M Ansell; Rhett P Ketterling; Karen L Rech; Andrew L Feldman
Journal:  Hum Pathol       Date:  2017-01-30       Impact factor: 3.466

6.  Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing.

Authors:  Jess F Peterson; Kathryn E Pearce; Reid G Meyer; Patricia T Greipp; Ryan A Knudson; Linda B Baughn; Rhett P Ketterling; Andrew L Feldman
Journal:  Histopathology       Date:  2020-01-17       Impact factor: 5.087

7.  Polymorphisms in microRNA-related genes are associated with survival of patients with T-cell lymphoma.

Authors:  Xi Li; Xiaobo Tian; Bo Zhang; Jieping Chen
Journal:  Oncologist       Date:  2014-02-21

8.  DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study.

Authors:  Martin Bjerregård Pedersen; Stephen Jacques Hamilton-Dutoit; Knud Bendix; Rhett P Ketterling; Patrick P Bedroske; Ivy M Luoma; Christopher A Sattler; Rebecca L Boddicker; N Nora Bennani; Peter Nørgaard; Michael Boe Møller; Torben Steiniche; Francesco d'Amore; Andrew L Feldman
Journal:  Blood       Date:  2017-05-18       Impact factor: 22.113

9.  Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Michael J Conte; Deborah A Bowen; Gregory A Wiseman; Kari G Rabe; Susan L Slager; Susan M Schwager; Timothy G Call; David S Viswanatha; Clive S Zent
Journal:  Leuk Lymphoma       Date:  2014-02-17

10.  Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.

Authors:  Stephen J Murphy; Robert J Karnes; Farhad Kosari; B Edgardo R Parilla Castellar; Benjamin R Kipp; Sarah H Johnson; Simone Terra; Faye R Harris; Geoffrey C Halling; Janet L Schaefer Klein; Aqsa Nasir; Eric Bergstrahl; Laureano J Rangel; William R Sukov; George Vasmatzis; John C Cheville
Journal:  Mod Pathol       Date:  2015-11-27       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.